Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | MTHFD2 | P13995 | 8/20 | 0.39 |
| ▸ | CLPP | Q16740 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30282693 | 1.00 | ROCK2 (0.42) | ROCK2CYP3A4MTHFD2CLPPMAPT | |
| SCHEMBL23973779 | 1.00 | ROCK2 (0.42) | ROCK2CYP3A4MTHFD2CLPPMAPT | |
| SCHEMBL23972214 | 0.96 | MTHFD2 (0.42) | ROCK2CYP3A4MTHFD2CLPPMAPT | |
| SCHEMBL23973729 | 0.96 | MTHFD2 (0.42) | ROCK2CYP3A4MTHFD2CLPPMAPT | |
| SCHEMBL30283793 | 0.95 | MTHFD2 (0.40) | ROCK2CYP3A4MTHFD2CLPPMAPT | |
| SCHEMBL31406779 | 0.95 | ROCK2 (0.38) | ROCK2CYP3A4MTHFD2CLPPMAPT | |
| SCHEMBL23972998 | 0.95 | MTHFD2 (0.40) | ROCK2CYP3A4MTHFD2CLPPMAPT | |
| SCHEMBL23973366 | 0.95 | ROCK2 (0.38) | ROCK2CYP3A4MTHFD2CLPPMAPT | |
| SCHEMBL23973585 | 0.95 | ROCK2 (0.41) | ROCK2CYP3A4MTHFD2CLPPMAPT | |
| SCHEMBL30284033 | 0.95 | ROCK2 (0.41) | ROCK2CYP3A4MTHFD2CLPPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255965-A1 | TRPV4 INHIBITOR AS A THERAPEUTIC AGENT FOR OCULAR DISEASES | RAQUALIA PHARMA INC. (JP) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255965-A1 | TRPV4 INHIBITOR AS A THERAPEUTIC AGENT FOR OCULAR DISEASES | TRPV4, TRPV5, TRPV2 | ROCK2 888/4885CYP3A4 2664/4885MTHFD2 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.